HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $60 to $69.
August 09, 2024 | 8:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Crinetics Pharmaceuticals and raises the price target from $60 to $69.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100